Background: PET-CT has emerged as a useful tool in the modern rheumatologist's armoury when facing certain diagnostic challenges. The Royal College of Physician's (RCP) guidance on the indications for PET-CT includes large vessel vasculitis (LVV), sarcoidosis and pyrexia of unknown origin (PUO) in specific circumstances. Within the North West England rheumatology community, potential barriers to the use of PET-CT were identified, including uncertainties about the availability of PET-CT for non-oncological indications, referral route and waiting times. Discussion with the regional PET-CT centre highlighted variability in the clinical information provided on referrals, which may impact on the urgency or interpretation of imaging. Thus development of a regional referral pathway for PET-CT was proposed. As the first step, we aimed to undertake a retrospective audit of referrals from rheumatologists to a regional PET-CT centre in addition to reviewing referrals for suspected LVV from other specialties.
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Methods: The audit standard was the 2013 RCP guidelines on the indications for PET-CT. Cases were identified from December 2013 to August 2015. Referral letters and reports were reviewed. Recorded variables included referring centre and specialty; clinical details, including referral reason, inflammatory markers, steroids/immunosuppressant therapy and previous imaging; time from referral to scan and key findings. Results: A total of 39 cases were reviewed. Nineteen patients were female (48.7%) and the median age was 40 years [interquartile range (IQR) 63-57]. The median time from referral to scan was 14 days (range 1-57). Thirty of 39 (77%) referrals were made by rheumatologists from 12 Trusts. Indications and key findings are described in Table 1 . In all cases referrals met the audit standard. Intermediate vascular uptake was reported on nine scans but was inconclusive for vasculitis. In some cases vascular uptake was reported using a semi-quantitative scale and in others in descriptive form. Information on inflammatory markers was provided in 16/39 (41%) cases. Steroid/immunosuppression use was reported in 32/39 (82%) cases. In cases where intermediate vascular uptake was seen, two patients were on steroids and in four cases no information was provided. Previous imaging information was provided in 16/39 (41%) cases. Prior to referral, 11 patients had a CT scan, 5 had an MRI, 1 had a labelled white cell scan and another had an isotope bone scan. Conclusion: While all referrals were for appropriate indications, important information regarding inflammatory markers and medication was lacking in some cases, which may have an impact on scan interpretation. There were variations in reporting methods and intermediate cases may benefit from multidisciplinary team discussion. Going forward, a regional user survey is being undertaken. Collaboration with other regional PET-CT centres has been initiated with the aim of optimising acquisition and reporting methods. A referral pathway including a pro forma with minimal clinical information is being designed. As a result, we aim to optimize the use of PET-CT within the region. 
